Division of Gastroenterology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan; Division of Gastroenterology, Department of Internal Medicine, Tri-Service General Hospital Songshan Branch, Taipei, Taiwan.
Division of Gastroenterology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.
Am J Med Sci. 2020 Aug;360(2):161-165. doi: 10.1016/j.amjms.2020.04.031. Epub 2020 May 4.
Nonalcoholic fatty liver disease (NAFLD) is regarded as a feature of metabolic syndrome in the liver. Metabolic syndrome is associated with a higher risk of bladder cancer. However, the association between NAFLD and bladder cancer is unclear. We aimed to investigate the association between NAFLD and bladder cancer.
The records of all patients (n = 251) diagnosed with the bladder cancer in our hospital between 2009 and 2013 were reviewed. We also randomly collected the records of adults without cancer (n = 266) as the control group. Clinical characteristics, biochemical tests for liver and metabolic function and abdominal computed tomography were assessed.
The incidence of NAFLD was 12.0% in the bladder cancer group and 4.9% in the control group. By multiple logistic regression analysis, NAFLD (P = 0.007; odds ratio [OR]: 2.61; 95% confidence interval [CI]: 1.30-5.22), male sex (P < 0.001; OR: 2.34; 95% CI: 1.61-3.41) and use of lipid lowering drugs (P = 0.001; OR: 0.43; 95% CI: 0.26-0.72) showed significant associations with bladder cancer. In bladder cancer patients, the median survival time was significantly longer in patients without NAFLD than in these with NAFLD (40 months versus 21.5 months, P = 0.022).
NAFLD was positively associated with bladder cancer and was a poor prognostic factor of bladder cancer. Further studies are needed to confirm whether NAFLD is a factor for the development of bladder cancer.
非酒精性脂肪性肝病（NAFLD）被认为是肝脏代谢综合征的一个特征。代谢综合征与膀胱癌风险增加相关。然而，NAFLD 与膀胱癌之间的关联尚不清楚。本研究旨在探讨 NAFLD 与膀胱癌之间的关系。
回顾了 2009 年至 2013 年间我院诊断为膀胱癌的所有患者（n=251）的记录。我们还随机收集了无癌症的成年人（n=266）的记录作为对照组。评估了临床特征、肝和代谢功能的生化检查以及腹部 CT。
膀胱癌组中 NAFLD 的发病率为 12.0%，对照组为 4.9%。通过多因素 logistic 回归分析，NAFLD（P=0.007；比值比 [OR]：2.61；95%置信区间 [CI]：1.30-5.22）、男性（P<0.001；OR：2.34；95%CI：1.61-3.41）和使用降脂药物（P=0.001；OR：0.43；95%CI：0.26-0.72）与膀胱癌显著相关。在膀胱癌患者中，无 NAFLD 患者的中位生存时间明显长于有 NAFLD 患者（40 个月与 21.5 个月，P=0.022）。
NAFLD 与膀胱癌呈正相关，是膀胱癌的不良预后因素。需要进一步的研究来证实 NAFLD 是否是膀胱癌发展的一个因素。
